On ECHEMI
Home > Drugs > Fusidic acid dry suspension

Fusidic acid dry suspension

Ingredients

Sodium fusidate.

Name Description Content CAS NO. Manufacturer
Sodium fusidateIngredients

751-94-0 12

Indication

It is mainly used to treat various infections caused by various sensitive bacteria, especially staphylococci, such as osteomyelitis, sepsis, endocarditis, recurrent cystic fibrosis, pneumonia, skin and soft tissue infections, surgical and traumatic infections, etc.

Usage and Dosage

Adults: 500 mg (1 bottle)/time, 3 times a day. Children and infants: 20 mg/kg body weight/day, divided into 3 doses. Dissolve 1 bottle (500 mg) of this powder for injection in 10 ml of the attached sterile buffer solution, and then dilute it with sodium chloride injection or 5% glucose injection to 250-500 ml for intravenous infusion. If the glucose injection is too acidic, the solution will be milky, and it cannot be used if this happens. The infusion time of each bottle should not be less than 2-4 hours. This product should be infused into a vein with good blood flow and a larger diameter, or into a central venous cannula to reduce the risk of venous spasm and thrombophlebitis. The intravenous infusion solution should be used up within 24 hours after preparation. Undiluted sodium fusidate solution must not be directly injected intravenously. To avoid local tissue damage, this product must not be injected intramuscularly or subcutaneously. According to the metabolism and excretion characteristics of sodium fusidate, patients with renal insufficiency and hemodialysis do not need to adjust the dosage of this product, and the dialysis clearance of this product is not high.

Adverse Reactions

Intravenous injection of this product may cause thrombophlebitis and venous spasm. Reversible increase in transaminases has been reported when taking 1.5-3 grams per day. There have been reports of reversible jaundice in some patients after taking the drug, which is mainly seen in large-dose intravenous administration, especially in patients with severe Staphylococcus aureus bacteremia. If jaundice persists, the drug should be discontinued, and serum bilirubin will return to normal. Reports of allergic reactions are very rare.

Storage

Store at room temperature

Packaging Specification

0.25 g

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.